Safety of using genetic engineering biological agents in rheumatoid arthritis
The paper reviews the current trials of the safety of using genetic engineering biological agents (GEBA) in patients with rheumatoid arthritis. It is stated that before its start, GEBA therapy calls for thorough screening of patients to rule out communicable diseases (including tuberculosis) or a hi...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2010-03-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/272 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849303435750408192 |
|---|---|
| author | N V Chichasova E L Nasonov N V Chichasova E L Nasonov |
| author_facet | N V Chichasova E L Nasonov N V Chichasova E L Nasonov |
| author_sort | N V Chichasova |
| collection | DOAJ |
| description | The paper reviews the current trials of the safety of using genetic engineering biological agents (GEBA) in patients with rheumatoid arthritis. It is stated that before its start, GEBA therapy calls for thorough screening of patients to rule out communicable diseases (including tuberculosis) or a high risk for infections (chronic shin ulcers, severe diabetes mellitus, persistent lung infection, and the presence of a urinary catheter), cancer, and severe visceral diseases. The baseline liver status, a cardiovascular risk, neutropenia in response to basic anti-inflammatory drugs (BAID) should be also borne in mind. It is noted that when patients are correctly selected and possible adverse reactions are monitored, GEBA therapy is not worse tolerated than is BAID therapy. |
| format | Article |
| id | doaj-art-1740392211b349e4b2fdfd55b7eeb3bb |
| institution | Kabale University |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2010-03-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-1740392211b349e4b2fdfd55b7eeb3bb2025-08-20T03:59:57ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2010-03-0141465810.14412/1996-7012-2010-5871577Safety of using genetic engineering biological agents in rheumatoid arthritisN V ChichasovaE L NasonovN V ChichasovaE L NasonovThe paper reviews the current trials of the safety of using genetic engineering biological agents (GEBA) in patients with rheumatoid arthritis. It is stated that before its start, GEBA therapy calls for thorough screening of patients to rule out communicable diseases (including tuberculosis) or a high risk for infections (chronic shin ulcers, severe diabetes mellitus, persistent lung infection, and the presence of a urinary catheter), cancer, and severe visceral diseases. The baseline liver status, a cardiovascular risk, neutropenia in response to basic anti-inflammatory drugs (BAID) should be also borne in mind. It is noted that when patients are correctly selected and possible adverse reactions are monitored, GEBA therapy is not worse tolerated than is BAID therapy.https://mrj.ima-press.net/mrj/article/view/272rheumatoid arthritisgenetic engineering biological agents |
| spellingShingle | N V Chichasova E L Nasonov N V Chichasova E L Nasonov Safety of using genetic engineering biological agents in rheumatoid arthritis Современная ревматология rheumatoid arthritis genetic engineering biological agents |
| title | Safety of using genetic engineering biological agents in rheumatoid arthritis |
| title_full | Safety of using genetic engineering biological agents in rheumatoid arthritis |
| title_fullStr | Safety of using genetic engineering biological agents in rheumatoid arthritis |
| title_full_unstemmed | Safety of using genetic engineering biological agents in rheumatoid arthritis |
| title_short | Safety of using genetic engineering biological agents in rheumatoid arthritis |
| title_sort | safety of using genetic engineering biological agents in rheumatoid arthritis |
| topic | rheumatoid arthritis genetic engineering biological agents |
| url | https://mrj.ima-press.net/mrj/article/view/272 |
| work_keys_str_mv | AT nvchichasova safetyofusinggeneticengineeringbiologicalagentsinrheumatoidarthritis AT elnasonov safetyofusinggeneticengineeringbiologicalagentsinrheumatoidarthritis AT nvchichasova safetyofusinggeneticengineeringbiologicalagentsinrheumatoidarthritis AT elnasonov safetyofusinggeneticengineeringbiologicalagentsinrheumatoidarthritis |